ANDREA CAVALUZZI: Open Payments
NPI 1881239648 · ELMIRA, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,236 in 187 payments from 14 companies in 2025. Trend: 2023 $1,306 · 2024 $2,603 · 2025 $3,236
Food & beverage: $3,236
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 33 | $794 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 23 | $484 |
| Neurocrine BioSciences, Inc. | 28 | $481 |
| Teva Pharmaceuticals USA, Inc. | 43 | $456 |
| Alkermes, Inc. | 14 | $294 |
| E.R. Squibb & Sons, L.L.C. | 16 | $237 |
| Supernus Pharmaceuticals, Inc. | 14 | $171 |
| Lundbeck LLC | 5 | $102 |
| Otsuka America Pharmaceutical, Inc. | 3 | $72 |
| Vanda Pharmaceuticals Inc. | 2 | $46 |
Products named: VRAYLAR, CAPLYTA, INGREZZA, UZEDY, ARISTADA, COBENFY, REXULTI, Qelbree.
Industry payments across NY — which companies pay providers there.
